{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:51:38Z","timestamp":1759042298625},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1007\/s11940-001-0038-1","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T18:29:09Z","timestamp":1180981749000},"page":"333-346","source":"Crossref","is-referenced-by-count":10,"title":["Anxiety disorders in neurologic illness"],"prefix":"10.1007","volume":"3","author":[{"given":"Robert D.","family":"Davies","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherri L.","family":"Gabbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula D.","family":"Riggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"38_CR1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","volume":"51","author":"RC Kessler","year":"1994","unstructured":"Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994, 51:8\u201319.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/ajp.147.2.252-a","volume":"147","author":"MB Stein","year":"1990","unstructured":"Stein MB, Heuser IJ, Juncos JL, et al.: Anxiety disorders in patients with Parkinson\u2019s disease. Am J Psychiatry 1990, 147:217\u2013220.","journal-title":"Am J Psychiatry"},{"key":"38_CR3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/jnp.8.4.383","volume":"8","author":"JH Richard","year":"1996","unstructured":"Richard JH, Schiffer RB, Kurtan R: Anxiety and Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 1996, 8:383\u2013392.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"38_CR4","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Press; 1994.","edition":"edn 4"},{"key":"38_CR5","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1001\/jama.283.19.2529","volume":"283","author":"DH Barlow","year":"2000","unstructured":"Barlow DH, Gorman JM, Shear MK, et al.: Cognitivebehavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000, 283:2529\u20132536.","journal-title":"JAMA"},{"key":"38_CR6","first-page":"98","volume":"4","author":"MG Wise","year":"1999","unstructured":"Wise MG, Rundell JR: Anxiety and neurological disorders. Semin Clin Neuropsychiatry 1999, 4:98\u2013102. Excellent review of diagnostic issues and treatment options for anxiety occurring in neurological conditions.","journal-title":"Semin Clin Neuropsychiatry"},{"key":"38_CR7","first-page":"S53","volume":"53","author":"TA Ketter","year":"1999","unstructured":"Ketter TA, Post RM, Theodore WH: Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999, 53(suppl):S53\u201367.","journal-title":"Neurology"},{"key":"38_CR8","first-page":"27","volume":"55","author":"E Hollander","year":"1994","unstructured":"Hollander E, Cohen LJ: The assessment and treatment of refractory anxiety. J Clin Psychiatry 1994, 55(suppl):27\u201331.","journal-title":"J Clin Psychiatry"},{"issue":"suppl A","key":"38_CR9","first-page":"A22","volume":"64","author":"RD Davies","year":"2000","unstructured":"Davies RD, Dubovsky SL, Gabbert S, et al.: Treatment resistance in anxiety disorders. Bull Menninger Clin 2000, 64(suppl A):A22-A36.","journal-title":"Bull Menninger Clin"},{"key":"38_CR10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/anxi.3070010402","volume":"1","author":"PP Roy-Byrne","year":"1994-1995","unstructured":"Roy-Byrne PP, Cowley DS: Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety 1994-1995, 1:151\u2013160.","journal-title":"Anxiety"},{"key":"38_CR11","first-page":"555","volume":"58","author":"DS Cowley","year":"1997","unstructured":"Cowley DS, Ha EH, Roy-Byrne PP: Determinants of pharmacologic treatment failure in panic disorder. Br J Psychiatry 1997, 58:555\u2013561.","journal-title":"Br J Psychiatry"},{"key":"38_CR12","first-page":"103","volume":"4","author":"AM Riether","year":"1999","unstructured":"Riether AM: Anxiety in patients with multiple sclerosis. Semin Clin Neuropsychiatry 1999, 4:103\u2013113. Detailed discussion of the complex interplay between multiple sclerosis, the treatment of multiple sclerosis, and comborbid anxiety.","journal-title":"Semin Clin Neuropsychiatry"},{"key":"38_CR13","first-page":"289","volume":"54","author":"DL Rosenstein","year":"1993","unstructured":"Rosenstein DL, Nelson JC, Jacobs SC: Seizures associated with antidepressants: a review. J Clin Psychiatry 1993, 54:289\u2013299.","journal-title":"J Clin Psychiatry"},{"key":"38_CR14","first-page":"274","volume":"148","author":"EC Lauterbach","year":"1991","unstructured":"Lauterbach EC, Duvoisin RC: Anxiety disorders in familial parkinsonism [letter to the editor]. Am J Psychiatry 1991, 148:274.","journal-title":"Am J Psychiatry"},{"key":"38_CR15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archpsyc.1991.01810360033005","volume":"48","author":"N Breslau","year":"1991","unstructured":"Breslau N, Kilbey M, Andreski P: Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psychiatry 1991, 48:1069\u20131074.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archpsyc.1992.01820110031004","volume":"49","author":"M Bruce","year":"1992","unstructured":"Bruce M, Scott N, Shine P, et al.: Anxiogenic effects of caffeine in patients with anxiety disorders. Arch Gen Psychiatry 1992, 49:867\u2013869.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-3999(97)00203-1","volume":"44","author":"M Bourin","year":"1998","unstructured":"Bourin M, Baker GB, Badwejn J: Neurobiology of panic disorder. J Psychosom Res 1998, 44:163\u2013180.","journal-title":"J Psychosom Res"},{"key":"38_CR18","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1176\/ps.50.10.1359","volume":"50","author":"MD Roberts","year":"1999","unstructured":"Roberts MD, Emsley RA, Pienaar WP, et al.: Anxiety disorders among abstinent alcohol-dependent patients. Psychiatr Serv 1999, 50:1359\u20131361.","journal-title":"Psychiatr Serv"},{"issue":"suppl 2","key":"38_CR19","first-page":"46","volume":"58","author":"JR Marshall","year":"1997","unstructured":"Marshall JR: Alcohol and substance abuse in panic disorder. J Clin Psychiatry 1997, 58(suppl 2):46\u201349.","journal-title":"J Clin Psychiatry"},{"issue":"suppl 1","key":"38_CR20","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0165-0327(98)00089-5","volume":"50","author":"JP Lepine","year":"1998","unstructured":"Lepine JP, Pelissolo A: Social phobia and alcoholism: a complex relationship. J Affect Disord 1998, 50(suppl 1):S23-S28.","journal-title":"J Affect Disord"},{"key":"38_CR21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/10826089909035650","volume":"34","author":"A Mackenzie","year":"1999","unstructured":"Mackenzie A, Funderburk FR, Allen RP: Sleep, anxiety, and depression in abstinent and drinking alcoholics. Subst Use Misuse 1999, 34:347\u2013361.","journal-title":"Subst Use Misuse"},{"key":"38_CR22","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1001\/jama.284.18.2348","volume":"284","author":"JG Johnson","year":"2000","unstructured":"Johnson JG, Cohen P, Pine DS, et al.: Association between cigarette smoking and anxiety during adolescence and early adulthood. JAMA 2000, 284:2348\u20132351.","journal-title":"JAMA"},{"key":"38_CR23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0272-7358(99)00027-6","volume":"20","author":"MG Kushner","year":"2000","unstructured":"Kushner MG, Abrams K, Borchardt C: The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 2000, 20:149\u2013171.","journal-title":"Clin Psychol Rev"},{"key":"38_CR24","doi-asserted-by":"crossref","unstructured":"Dick CL, Bland RC, Newman SC: Panic disorder. Acta Psychiatr Scand Suppl 1994, 45\u201353.","DOI":"10.1111\/j.1600-0447.1994.tb05790.x"},{"key":"38_CR25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0887-6185(98)00031-0","volume":"12","author":"L Turgeon","year":"1998","unstructured":"Turgeon L, Marchand A, Dupuis G: Clinical features in panic disorder with agoraphobia: a comparison of men and women. J Anxiety Disord 1998, 12:539\u2013553.","journal-title":"J Anxiety Disord"},{"key":"38_CR26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/acm.1999.5.237","volume":"5","author":"SK Johnson","year":"1999","unstructured":"Johnson SK, Frederick J, Kaufman M, et al.: A controlled investigation of bodywork in multiple sclerosis. J Altern Complement Med 1999, 5:237\u2013243.","journal-title":"J Altern Complement Med"},{"key":"38_CR27","first-page":"70","volume":"5","author":"C Husted","year":"1999","unstructured":"Husted C, Pham L, Hekking A, et al.: Improving quality of life for people with chronic conditions: the example of t\u2019ai chi and multiple sclerosis. Altern Ther Health Med 1999, 5:70\u201374.","journal-title":"Altern Ther Health Med"},{"key":"38_CR28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.52.1.57","volume":"52","author":"A Solari","year":"1999","unstructured":"Solari A, Filippini G, Gasco P, et al.: Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999, 52:57\u201362.","journal-title":"Neurology"},{"issue":"suppl 1","key":"38_CR29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/(SICI)1520-6394(1998)8:1+<114::AID-DA17>3.0.CO;2-S","volume":"8","author":"AW Goddard","year":"1998","unstructured":"Goddard AW, Charney DS: SSRIs in the treatment of panic disorder. Depress Anxiety 1998, 8(suppl 1):114\u2013120.","journal-title":"Depress Anxiety"},{"issue":"suppl 8","key":"38_CR30","first-page":"24","volume":"59","author":"DJ Nutt","year":"1998","unstructured":"Nutt DJ: Antidepressants in panic disorder: clinical and preclinical mechanisms. J Clin Psychiatry 1998, 59(suppl 8):24\u201328.","journal-title":"J Clin Psychiatry"},{"key":"38_CR31","first-page":"207","volume":"34","author":"LA Papp","year":"1998","unstructured":"Papp LA, Sinha SS, Martinez JM, et al.: Low-dose venlafaxine treatment of panic disorder. Psychopharmacol Bull 1998, 34:207\u2013209.","journal-title":"Psychopharmacol Bull"},{"key":"38_CR32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/10401239909147053","volume":"11","author":"LL Carpenter","year":"1999","unstructured":"Carpenter LL, Leon Z, Yasmin S, et al.: Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999, 11:81\u201386.","journal-title":"Ann Clin Psychiatry"},{"key":"38_CR33","first-page":"245","volume":"57","author":"NA DeMartinis","year":"1996","unstructured":"DeMartinis NA, Schweizer E, Rickels K: An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996, 57:245\u2013258.","journal-title":"J Clin Psychiatry"},{"key":"38_CR34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archpsyc.1988.01800290027004","volume":"45","author":"JC Ballenger","year":"1988","unstructured":"Ballenger JC, Burrows GD, DuPont RL, et al.: Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: Efficacy in shortterm treatment. Arch Gen Psychiatry 1988, 45:413\u2013422.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/10401239509149042","volume":"7","author":"KV Harvey","year":"1995","unstructured":"Harvey KV, Balon R: Augmentation with buspirone: a review. Ann Clin Psychiatry 1995, 7:143\u2013147.","journal-title":"Ann Clin Psychiatry"},{"issue":"suppl 10","key":"38_CR36","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1528-1157.1999.tb00883.x","volume":"40","author":"R Torta","year":"1999","unstructured":"Torta R, Keller R: Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999, 40(suppl 10):S2-S20. Excellent summary of the association between seizure activity and psychiatric symptoms. Particularly good discussion of the possible etiologies behind this relationship.","journal-title":"Epilepsia"},{"key":"38_CR37","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/00004583-199709000-00023","volume":"36","author":"DO Lee","year":"1997","unstructured":"Lee DO, Helmers SL, Steingard RJ, et al.: Case study: seizure disorder presenting as panic disorder with agoraphobia. J Am Acad Child Adolesc Psychiatry 1997, 36:1295\u20131298.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"suppl 22","key":"38_CR38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0333102498018S2210","volume":"18","author":"N Breslau","year":"1998","unstructured":"Breslau N: Psychiatric comorbidity in migraine. Cephalalgia 1998, 18(suppl 22):56\u201361.","journal-title":"Cephalalgia"},{"key":"38_CR39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000119182","volume":"31","author":"D Marazziti","year":"1995","unstructured":"Marazziti D, Toni C, Pedri S, et al.: Headache, panic disorder and depression: comorbidity or a spectrum? Neuropsychobiology 1995, 31:125\u2013129.","journal-title":"Neuropsychobiology"},{"key":"38_CR40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0733-8619(05)70298-X","volume":"15","author":"KR Merikangas","year":"1997","unstructured":"Merikangas KR, Stevens DE: Comorbidity of migraine and psychiatric disorders. Neurol Clin 1997, 15:115\u2013123.","journal-title":"Neurol Clin"},{"key":"38_CR41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/10401239409148999","volume":"6","author":"PE Keck","year":"1994","unstructured":"Keck PE, Merikangas KR, McElroy SL, et al.: Diagnostic and treatment implications of psychiatric comorbidity with migraine. Ann Clin Psychiatry 1994, 6:165\u2013171.","journal-title":"Ann Clin Psychiatry"},{"key":"38_CR42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/070674379804300109","volume":"43","author":"M Baetz","year":"1998","unstructured":"Baetz M, Bowen RC: Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998, 43:73\u201377.","journal-title":"Can J Psychiatry"},{"key":"38_CR43","first-page":"78","volume":"17","author":"A Ontiveros","year":"1992","unstructured":"Ontiveros A, Fontaine R: Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992, 17:78\u201380.","journal-title":"J Psychiatry Neurosci"},{"key":"38_CR44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002130050578","volume":"136","author":"G Laakmann","year":"1998","unstructured":"Laakmann, G, Schule C, Lorkowski G, et al.: Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharm 1998, 136:357\u2013366.","journal-title":"Psychopharm"},{"key":"38_CR45","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v60n0805","volume":"60","author":"JR Davidson","year":"1999","unstructured":"Davidson JR, DuPont RL, Hedges D, et al.: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999, 60:528\u2013535.","journal-title":"J Clin Psychiatry"},{"key":"38_CR46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4088\/JCP.v60n0705","volume":"60","author":"PJ Goodnick","year":"1999","unstructured":"Goodnick PJ, Puig A, DeVane CL, et al.: Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 1999, 60:446\u2013448.","journal-title":"J Clin Psychiatry"},{"key":"38_CR47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002826-198608000-00004","volume":"9","author":"CL Ludwig","year":"1986","unstructured":"Ludwig CL, Weinberger DR, Bruno G, et al.: Buspirone, Parkinson\u2019s disease, and the locus ceruleus. Clin Neuropharmacol 1986, 9:373\u2013378.","journal-title":"Clin Neuropharmacol"},{"key":"38_CR48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","volume":"17","author":"V Bonifati","year":"1994","unstructured":"Bonifati V, Fabrizio E, Cipriani R, et al.: Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994, 17:73\u201382.","journal-title":"Clin Neuropharmacol"},{"key":"38_CR49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archpsyc.1996.01830020077009","volume":"53","author":"WJ Magee","year":"1996","unstructured":"Magee WJ, Eaton WW, Wittchen HU, et al.: Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 1996, 53:159\u2013168.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199312000-00008","volume":"13","author":"JR Davidson","year":"1993","unstructured":"Davidson JR, Potts NS, Richichi E, et al.: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharm 1993, 13:423\u2013428.","journal-title":"J Clin Psychopharm"},{"key":"38_CR51","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0005-7967(96)00028-9","volume":"34","author":"SM Turner","year":"1996","unstructured":"Turner SM, Beidel DC, Wolff PL, et al.: Clinical features affecting treatment outcome in social phobia. Behav Res Ther 1996, 34:795\u2013804.","journal-title":"Behav Res Ther"},{"key":"38_CR52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","volume":"175","author":"D Baldwin","year":"1999","unstructured":"Baldwin D, Bobes J, Stein D, et al.: Paroxetine in social phobia\/social anxiety disorder. Br J Psychiatry 1999, 175:120\u2013126.","journal-title":"Br J Psychiatry"},{"key":"38_CR53","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00004714-199208000-00022","volume":"12","author":"B Black","year":"1992","unstructured":"Black B, Uhde TW, Tancer ME: Fluoxetine for the treatment of social phobia. J Clin Psychopharm 1992, 12:293\u2013295.","journal-title":"J Clin Psychopharm"},{"key":"38_CR54","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.152.9.1368","volume":"152","author":"DJ Katzelnick","year":"1995","unstructured":"Katzelnick DJ, Kobak KA, Greist JH, et al.: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995, 152:1368\u20131371.","journal-title":"Am J Psychiatry"},{"key":"38_CR55","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","volume":"156","author":"MB Stein","year":"1999","unstructured":"Stein MB, Fyer AJ, Davidson JR, et al.: Fluvoxamine in the treatment of social phobia: a double-blind, placebo-controlled study. Am J Psychiatry 1999, 156:756\u2013760.","journal-title":"Am J Psychiatry"},{"key":"38_CR56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","volume":"49","author":"MR Liebowitz","year":"1992","unstructured":"Liebowitz MR, Schneier P, Campeas R, et al.: Phenelzine vs atenolol in social phobia: a placebo controlled trial. Arch Gen Psychiatry 1992, 49:290\u2013300.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR57","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I","volume":"15","author":"S Tesei","year":"2000","unstructured":"Tesei S, Antonini A, Canesi M, et al.: Tolerability of paroxetine in Parkinson\u2019s disease: a prospective study. Mov Disord 2000, 15:986\u2013989.","journal-title":"Mov Disord"},{"key":"38_CR58","first-page":"4","volume":"53","author":"SA Rasmussen","year":"1992","unstructured":"Rasmussen SA, Eisen JL: The epidemiology and differential diagnosis of obsessive-compulsive disorder. J Clin Psychiatry 1992, 53(suppl):4\u201310.","journal-title":"J Clin Psychiatry"},{"key":"38_CR59","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archpsyc.1986.01800120066013","volume":"43","author":"DL Pauls","year":"1986","unstructured":"Pauls DL, Towbin KE, Leckman JF, et al.: Gilles de la Tourette\u2019s syndrome and obsessive-compulsive disorder. Arch Gen Psychiatry 1986, 43:1180\u20131182.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0272-7358(98)00059-2","volume":"19","author":"DM Sheppard","year":"1999","unstructured":"Sheppard DM, Bradshaw JL, Purcell R, et al.: Tourette\u2019s and comorbid syndromes: obsessive compulsive and attention deficit hyperactivity disorder. A common etiology? Clin Psychol Rev 1999, 19:531\u201352.","journal-title":"A common etiology? Clin Psychol Rev"},{"key":"38_CR61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","volume":"52","author":"JH Greist","year":"1995","unstructured":"Greist JH, Chouinard G, Duboff E, et al.: Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995, 52:289\u2013295.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR62","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","volume":"51","author":"GD Tollefson","year":"1994","unstructured":"Tollefson GD, Rampey AH, Potvin JH, et al.: A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994, 51:559\u2013567.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR63","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1192\/bjp.169.4.468","volume":"69","author":"J Zohar","year":"1996","unstructured":"Zohar J, Judge R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996, 69:468\u2013474.","journal-title":"Br J Psychiatry"},{"key":"38_CR64","first-page":"423","volume":"56","author":"FM Jacobsen","year":"1995","unstructured":"Jacobsen FM: Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995, 56:423\u2013429.","journal-title":"J Clin Psychiatry"},{"key":"38_CR65","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","volume":"51","author":"CJ McDougle","year":"1994","unstructured":"McDougle CJ, Goodman WK, Leckman JF, et al.: Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1994, 51:302\u2013306.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR66","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4088\/JCP.v60n0804","volume":"60","author":"EL Weiss","year":"1999","unstructured":"Weiss EL, Potenza MN, McDougle CJ, et al.: Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an openlabel case series. J Clin Psychiatry 1999, 60:524\u2013527.","journal-title":"J Clin Psychiatry"},{"key":"38_CR67","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","volume":"57","author":"CJ McDougle","year":"2000","unstructured":"McDougle CJ, Epperson CN, Pelton GH, et al.: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000, 57:794\u2013801.","journal-title":"Arch Gen Psychiatry"},{"key":"38_CR68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1017\/S1092852900021623","volume":"5","author":"S Rasmussen","year":"2000","unstructured":"Rasmussen S, Greenberg B, Mindus P, et al.: Neurosurgical approaches to intractable obsessivecompulsive disorder. CNS Spectrums 2000, 5:23\u201334. Concise review of the history of surgical interventions for OCD, as well as the current status of this treatment.","journal-title":"CNS Spectrums"},{"key":"38_CR69","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","volume":"19","author":"AC Pande","year":"1999","unstructured":"Pande AC, Davidson JR, Jefferson JW, et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharm 1999, 19:341\u2013348.","journal-title":"J Clin Psychopharm"},{"key":"38_CR70","first-page":"1","volume-title":"Clinical Handbook of Psychological Disorders","author":"MG Craske","year":"1993","unstructured":"Craske MG, Barlow DH: Panic disorder and agoraphobia. In In Clinical Handbook of Psychological Disorders, Second Edition. Edited by Barlow DH. New York: The Guilford Press, 1993:1\u201347.","edition":"Second Edition"},{"key":"38_CR71","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0193-953X(18)30025-X","volume":"18","author":"HR Juster","year":"1995","unstructured":"Juster HR, Heimberg RG: Social phobia: longitudinal course and long-term outcome of cognitivebehavioral treatment. Psychiatr Clin North Am 1995, 18:821\u2013842.","journal-title":"Psychiatr Clin North Am"},{"key":"38_CR72","volume-title":"Obsessive-compulsive disorders: psychological and pharmacological treatment","author":"EB Foa","year":"1985","unstructured":"Foa EB, Steketee GS, Milby JB: Behavior therapy with obsessive-compulsives: from theory to treatment. In Obsessive-compulsive disorders: psychological and pharmacological treatment. Edited by Mavissakalian M. New York: Plenum Press; 1985."},{"key":"38_CR73","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1528-1157.1998.tb01427.x","volume":"39","author":"AB Ettinger","year":"1998","unstructured":"Ettinger AB, Weisbrot DM, Nolan EE, et al.: Symptoms of depression and anxiety in pediatric epilepsy patients. Epilepsia 1998, 39:595\u2013599.","journal-title":"Epilepsia"},{"key":"38_CR74","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00004583-199506000-00017","volume":"34","author":"PD Riggs","year":"1995","unstructured":"Riggs PD, Baker S, Mikulich SK, et al.: Depression in substance-dependent delinquents. J Am Acad Child Adolesc Psychiatry 1995, 34:764\u2013771.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"38_CR75","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004583-200101000-00024","volume":"40","author":"K Manassis","year":"2001","unstructured":"Manassis K, Monga S: A therapeutic approach to children and adolescents with anxiety disorders and associated comorbid conditions. J Am Acad Child Adolesc Psychiatry 2001, 40:115\u2013117.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"38_CR76","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00004583-199601000-00019","volume":"35","author":"G Bernstein","year":"1996","unstructured":"Bernstein G, Borchardt CM, Perwien AR: Anxiety disorders in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996, 35:110\u20131119.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"38_CR77","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00004583-199309000-00044","volume":"32","author":"GA Bernstein","year":"1993","unstructured":"Bernstein GA, Shaw K: Practice parameters for the assessment and treatment of anxiety disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1993, 32:1089\u20131098.","journal-title":"J Am Acad Child Adolesc Psychiatry"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0038-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-001-0038-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0038-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:03:04Z","timestamp":1683867784000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-001-0038-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s11940-001-0038-1","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}